上海莱士：接受重阳投资调研

Group 1 - The core viewpoint of the article is that Shanghai Laishi (SZ 002252) announced an investor meeting scheduled for December 16, 2025, where key executives will address investor inquiries [1] - For the first half of 2025, Shanghai Laishi's revenue composition shows that blood products production and sales accounted for 99.21%, while diagnostic equipment and reagents made up 0.76%, and other businesses contributed 0.03% [1] - As of the report's release, Shanghai Laishi has a market capitalization of 42.4 billion yuan [1]